The Healthcare Spinoff Getting a Second Act Through Portfolio Surgery

When a company gets carved out of a larger conglomerate, it inherits stranded costs, a seller's investor base, and thin analyst coverage. 

The stock drifts while the actual business quietly gets cleaned up, and by the time the market catches on, the easy money is usually gone. Right now you are still in the window where the cleanup is finishing, but the multiple has not caught up.

A Q2 print that surprised on nearly every line

Solventum (NYSE: SOLV) reported Q2 adjusted EPS of $2.55 against a consensus of $1.91, a 34% beat. Revenue of $2.21 billion grew 2.2% on a reported basis but organic sales jumped 9.5% year over year, with strong performance across MedSurg, Dental, and Health Information Systems.

On the surface, that looks exceptional. And parts of it are. But a significant portion of the organic growth was pulled forward by advance ordering ahead of an ERP system transition.

Management estimated normalized organic growth at approximately 4%, which is a more realistic baseline to plan around going forward.

The adjusted operating margin came in at 28.4%, partly aided by a tariff refund and ERP-related timing.

Strip those items out and the underlying adjusted operating margin was roughly 21.7%. Still an improvement from prior periods, but less dramatic than the headline suggests.

The HIS separation is the forward catalyst

During Q2, management announced the intent to separate the Health Information Systems business as an independent entity. HIS contributes roughly 18% of total revenue and is primarily a software and revenue cycle management business.

Separating it allows the remaining company to operate as a focused medical technology firm with Dental and MedSurg at the center.

The guidance raise that came with Q2 reflected the improved trajectory. Full-year adjusted EPS guidance moved up to $7.10 to $7.20 from the prior $6.40 to $6.60.

That is a meaningful step up in the earnings outlook, even accounting for the one-time items that boosted Q2.

From conglomerate leftover to focused MedTech

When 3M spun out Solventum, the business had four segments, including Purification and Filtration, a lower-margin business with limited strategic fit. That was sold in late 2025. Now HIS is next.

What remains after HIS separates is a clean two-segment business: MedSurg (advanced wound care, infection prevention, surgical solutions) and Dental Solutions.

MedSurg makes up roughly 64% of current revenue, Dental roughly 18%. Both are higher-margin, recurring-need healthcare categories with exposure to hospital system spending and dental procedure volumes.

That is a meaningfully different earnings profile than a post-spinoff conglomerate overhang. Focused companies earn richer multiples. The re-rating case rests on the market repricing the residual business once the portfolio transformation is complete.

Bryan Hanson changed the operating culture

The CEO brought in to run this business came from the medical device world, with years running Zimmer Biomet. That background shows. The focus since his arrival has been on margin discipline, manufacturing consolidation, and capital allocation clarity.

Management has outlined a roadmap to expand adjusted operating margins meaningfully over the next two years.

The Q2 result, even adjusting for one-time items, showed the trajectory is real. SG&A spending came down, R&D expense declined, and adjusted operating income grew more than 30% year over year.

The discount is real and still there

Run the comparison. Becton Dickinson, Medtronic, and Zimmer Biomet all trade at forward earnings multiples in the mid-to-high teens. Solventum sits at roughly 12 to 13 times the guidance midpoint of $7.15.

Some of that discount is earned: the business is still in transition, the HIS separation adds uncertainty, and organic growth excluding timing benefits is in the low single digits. You are not buying a Stryker-grade growth profile here.

But you also do not need the full peer multiple to make money. Close half the gap and the stock moves significantly from current levels.

The template that rhymes most closely is Baxter International after its own portfolio cleanup, where the multiple expanded from single digits back toward the mid-teens as the balance sheet improved and guidance stabilized.

The leverage concern is real but manageable

Debt-to-equity sits above 100%. That is elevated for a medical technology business and one reason the stock has not fully closed the peer gap yet.

The Purification sale helped. The HIS separation, depending on how it is structured, will either generate cash or result in a cleaner capital structure.

Free cash flow of roughly $490 million over the trailing twelve months gives management the ability to continue paying down debt.

Once leverage improves to a more typical MedTech level, the multiple compression from financial risk starts to lift.

The 9.5% organic growth is not the real run rate.

That headline number was inflated by customers ordering early ahead of an ERP system cutover. Management itself told you the normalized figure is approximately 4%.

You should model around 3% to 4% organic growth for the remainder of the year, with some possibility of lapping the advance order benefit creating a temporary headwind.

That is still respectable for a business in transition. But if you bought the stock expecting 9.5% organic growth to persist, you will be disappointed. The Q2 beat was partially borrowed from future quarters.

The underlying margin improvement story is more durable than the top-line acceleration. Focus there.

Estimates have been moving downward since the earnings beat. Despite the strong Q2 print, analyst estimate revisions have trended negative in the weeks since.

That signals the market has concerns about the second half, possibly around the ERP timing unwind showing up as a headwind to organic growth.

The HIS separation creates transition uncertainty. Separating a business of this size takes time and money. Transition service agreements, shared costs, and operational complexity are real and will show up in near-term results before they show up as benefits.

Debt remains elevated. Until the balance sheet gets closer to peer-level leverage ratios, the multiple will carry a discount. Any deterioration in cash generation delays that improvement.

The Q2 beat included items that do not repeat. A tariff refund and ERP-related advance order timing both boosted Q2 results. Q3 and Q4 face harder comparisons. If the underlying business does not hold the margin trajectory without those benefits, guidance will get tested.

This is a spinoff finishing its cleanup at exactly the moment the portfolio strategy is crystallizing. The comparison to Baxter after its own restructuring is apt, and the gap between Solventum’s forward multiple and where focused MedTech companies trade is real.

The honest complication is timing. Analyst estimates are moving down despite a strong beat; the stock is not far from its 52-week high after the Q2 move, and the real margin trajectory will only become clear once the one-time items from Q2 work their way out.

This is not a value entry at these levels the way it would have been a year ago. But it is a name worth owning with a defined plan.

Accumulate on any pullback, watch Q3 for confirmation that underlying margins hold near 21% or better without the timing benefits, and let the HIS separation timeline become a re-rating event.

If Q3 shows organic growth decelerating sharply or margins compressing below 20%, reduce the position. The thesis needs the organic business to be clean and improving, not just boosted by one-time tailwinds.

Looking to buy? A pullback from current levels gives you a better entry than chasing the Q2 move. Watch for the stock to settle before adding size.

Already own it? Hold through the Q3 print in November and watch underlying organic growth and adjusted margins excluding one-time items. That is your scorecard.

Main risk to respect: Q2’s headline numbers were partially inflated, estimates are moving lower, and the HIS separation will create transition noise before it delivers clarity. Patience is required.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any names you want me to check out.

Best Regards,
—Noah Zelvis
Undervalued Edge